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The launch of the MinION Access Program has caused much activity within the scientific
community. MinION represents a keenly anticipated, novel addition to the current
melange of commercial sequencers. Driven by the nanopore sequencing mechanism
that requires minimal sample manipulation, the device is capable of generating long
sequence reads in sizes (up to or exceeding 50 kb) that surpass those of all other
platforms. One notable advantage of this feature is that long-range haplotypes can be
more accurately resolved; such advantage is particularly pertinent to the genotyping of
complex loci such as genes encoding the human leukocyte antigens, which are pivotal
determinants of drug hypersensitivity. With this timely, albeit brief, review, we set out to
examine the applications on which MinION has been tested thus far, the bioinformatics
workflow tailored to the unique characteristics of its extended sequence reads, the
device’s potential utility in the detection of genetic markers for drug hypersensitivity,
and how it may eventually evolve to become fit for diagnostic purposes in the clinical
setting.
Keywords: MinION, nanopore sequencing, drug hypersensitivity, sequence-based HLA typing, bioinformatics
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INTRODUCTION
The launch of the MinION Access Program by Oxford Nanopore Technologies (ONT), a UK-
based company specializing in nanopore sequencing, has caused much activity within the scientific
community. The device is a miniature, third-generation sequencer in which 512 nanopores are
housed and responsible for sensing single-stranded DNAs. With steadily improving sequencing
accuracy, MinION has been a much welcome addition to the melange of tools deployed for
diagnosing inherited drug hypersensitivity. The compact measurements of the device confer it such
a degree of portability that is unsurpassable by other platforms. There has even been speculation
that MinION could be transported to Mars and used to probe the existence of alien life forms
(Check Hayden, 2015). Thus far, the use of MinION has been directed largely toward DNA
sequencing; however, a broader range of MinION applications for RNA, microRNA, and protein
analysis are being explored. A scaled-up version of MinION, which is composed of 48 flow cells
and designated PromethION, has also been made available via another program, granting the
participants early access to the platform (Karow, 2015).
MinION: HISTORY AND APPLICATIONS
The characteristics of ion channels as nanopores for DNA molecule detection have been extensively
investigated since two decades ago (Kasianowicz et al., 1996; Howorka et al., 2001). When purified,
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single-stranded DNAs are passed through an array of pores
embedded onto a membrane, characteristic current patterns that
reflect the identities of DNA bases are produced (Clarke et al.,
2009; Ip et al., 2015). Various improvements in the experimental
setup have increased the accuracy of base-reading; these have
included modification of the structure of α-hemolysin channels,
addition of bulky cyclodextrin molecules to reduce the speed of
DNAs translocating through the pores, introduction of hairpin
polynucleotides to connect unzipped, double-stranded DNAs,
and adjustment of salt concentrations in the buffer to alter
the voltage across the membrane (Clarke et al., 2009; Brown
et al., 2012). These changes have ultimately led to the release of
MinION. Compared with existing second-generation sequencers
such as MiSeq and Ion Torrent that sequence up to 400 bp,
MinION is deemed ideal for DNA sequencing as it can generate
long reads up to or exceeding 50 kb (Jain et al., 2015). Moreover, it
does not require pre-amplification of the sample, which removes
potential bias in the data that could be introduced by polymerase
chain reactions (PCRs).
MinION has been tested in diverse applications, ranging
from early work on bacterial sequencing and identification, to
recent discovery of its ability to detect pathogens in human
plasma and that to distinguish methylated DNA bases from
their unmethylated counterparts (Figure 1). Extended sequences
generated by MinION have been used to supplement better
quality MiSeq data in constructing the genomes of Bacteroides
fragilis and Saccharomyces cerevisiae (Goodwin et al., 2015; Risse
et al., 2015). Further enhancement of bioinformatics workflow
has allowed de novo genome assembly for the Escherichia coli K-
12 MG1655 strain, whereby 98.4% nucleotide accuracy was noted
across the 4.6-mb reconstructed genome (Loman et al., 2015).
Such high-quality data output from the device has later been
translated into differentiating three closely related poxviruses,
namely cowpox, vaccinia-MVA, and vaccinia-Lister (Kilianski
et al., 2015). The portability of MinION and relatively rapid
sample preparation and data generation associated with the
sequencer have positioned it to be a useful tool in the recent
Ebola epidemic, wherein it was used on-site for monitoring the
evolution of Ebola virus in a series of clinical samples. Similar
principles of viral identification from human blood have also
been applied to sequencing chikungunya and hepatitis C viruses
(Greninger et al., 2015; Quick et al., 2016).
FIGURE 1 | MinION applications presented in chronological order.
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In the detection of DNA methylation patterns in human
samples, the subtle differences in the electrical signals produced
by methylated cytosine bases could also be picked up by MinION
(Simpson et al., 2016). This is an exciting breakthrough as
the conventional identification of these molecular modifications
requires a more complex and specialized sample preparation
approach, such as methylated DNA immunoprecipitation
followed by sequencing, or bisulfite genomic sequencing
(Frommer et al., 1992; Corley et al., 2015). Bisulfite sequencing,
the gold standard for detecting DNA methylation, indirectly
allows differentiation of methylated cytosines via selective
conversion of unmethylated cytosines to uracils, which are
then detected as thymine post-PCR (Li and Tollefsbol, 2011).
In contrast, the MinION-based workflow is much simpler: a
statistical model has been developed and optimized for direct
identification of 5-methylcytosine from samples prepared by
ONT’s standard protocol (Simpson et al., 2016). Though a direct
causal relationship between drug hypersensitivity and DNA
methylation has not been observed, the epigenetic phenomenon
has been proven to mediate other processes such as disease
pathogenesis and the effectiveness of a number of drugs
(Beyrouthy et al., 2009; Anier et al., 2010).
PROCESSING OF NANOPORE
SEQUENCING DATA
Central to the processing of nanopore sequencing data is the
hidden Markov model (Eddy, 2004), which has been applied
to various stages of sequence analysis from base-calling, fine-
tuning alignment, to variant discovery (Jain et al., 2015; Szalay
and Golovchenko, 2015). For base-calling, this model yields
statistical deductions about the underlying DNA sequences
(hidden state) based on a series of emitted observations. The
successive ionic perturbations (events) caused by 6-mer DNAs
(or 5-mer DNAs for now-obsolete workflows) that are drawn
through the nanopores are rendered into DNA sequences based
on known pairs of DNA sextets and corresponding current values
(Timp et al., 2012; Szalay and Golovchenko, 2015). A major
obstacle to this approach is that the current levels for all
possible 6-mer combinations comprise a continuum of electrical
signals rather than segregate into discrete patterns that could be
unambiguously interpreted. To tease out these ionic signatures,
additional clues are gained from neighboring sequences (Timp
et al., 2012). For instance, suppose we were to infer a 6-mer
DNA from an electrical signal, which indicated there were
two possibilities: TACGTA and TACGTT. We knew that, on
most occasions, the preceding sequence, ATACGT, was likely
to transition to TACGTA; thus TACGTA should have been the
sequence motif from which the signal had originated (Timp
et al., 2012). Though this example is rather simplistic, it serves
to illustrate the effectiveness of the Markov model. The emission
and transition probabilities can be derived from datasets that are
used to train the model.
Similarly, for sequence alignment, maximum likelihood
estimates can be computed for all nanopore sequencing error
types within a Markov network, i.e., insertions, deletions, and
substitutions. These estimates are then used to ascertain whether
a reference-discordant read is indeed misaligned. For instance,
as A–T or T–A miscalls are unlikely, sequence alignments
containing these mismatches may well have been incorrectly
placed. Alternately, the aligner may not be at fault and the
discrepancies may have arisen from inherent DNA variation (Jain
et al., 2015). This strategy has been extrapolated to enhance
alignments generated by existing aligners and subsequently detect
variants deliberately introduced into a phage genome reference
(Jain et al., 2015).
An example of a bioinformatics pipeline for MinION-
generated data is shown in Figure 2. Raw electrical signals can
be base-called by a tool provided by ONT, Metrichor, or other
open-source software (Boža et al., 2016; David et al., 2016). DNA
sequences produced from the nanopores are stored in the FAST5
format, alongside other types of data such as the run statistics. All
data are stratified and placed within predefined categories. Pre-
alignment processing typically requires extraction of FASTA or
FASTQ sequences from the FAST5 files, using Poretools (Python-
based; Loman and Quinlan, 2014) or poRe (written in R; Watson
et al., 2015). A number of long-read aligners have been tested
thus far on nanopore sequences, including BLASR, BWA-MEM,
LASTZ, and LAST. One of the challenges unique to long-read
alignment lies in quickly finding short matches, termed seeds or
anchors, between two sequences during a preliminary round of
alignment (Li and Durbin, 2009; Chaisson and Tesler, 2012; Li,
2013). With longer sequences, the numbers of possible matches
and mismatches are larger; hence, the operation of the aligners
would be affected, to a greater extent, by the efficiency of their
seed-and-extend algorithm.
BLASR and BWA-MEM first invoke Burrow-Wheelers
transform to create easily searchable, sorted strings (index)
of a reference genome to facilitate initial side-by-side check
that pinpoints short exact matches, which are subsequently
extended or refined to form longer DNA stretches (Chaisson
and Tesler, 2012; Li, 2013). LASTZ resembles BLASR and
BWA-MEM but with two principal variations. First, the aligner
employs a different indexing mechanism and dissects the
reference sequence into equally sized, overlapping segments to
ease sequence comparison. Second, it does not require perfect
similarity for qualifying a short match as an acceptable seed;
some degree of discrepancy is permitted (Harris, 2007). LAST
differs from LASTZ in that it can resolve repeat-rich sequences
more successfully (Kiełbasa et al., 2011). When aligned, the
sequences can be further scrutinized using NanoOK, which
works out the read-length distribution, the occurrence of k-mers,
the depths of coverage across targets, and other relevant statistics
(Leggett et al., 2015). With accurate alignments, high-confidence
DNA variant calls can then be generated.
PHARMACOGENETICS: A CLASSIC
CASE OF ABACAVIR HYPERSENSITIVITY
Abacavir, a nucleoside reverse-transcriptase inhibitor used to
treat HIV-1 infection, causes a potentially fatal hypersensitivity
reaction, to which Caucasians are notably susceptible, in 4–9%
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FIGURE 2 | An example of a pipeline for the processing of MinION data (A), (B–D) alongside additional notes for relevant bioinformatics-related
concepts.
of individuals exposed to the drug (Hetherington et al., 2002;
Mallal et al., 2002; Symonds et al., 2002; Martin et al., 2004).
Abacavir-induced hypersensitivity remains, to date, one of the
few rewarding examples of pharmacogenetics-guided therapy.
Genetic predisposition, specifically the presence of the HLA-
B∗57:01 allele (human leukocyte antigen), is a strong predictor
of abacavir hypersensitivity. The association, first reported in a
Western Australian population (Mallal et al., 2002), has since
been replicated in many other studies (Hetherington et al.,
2002; Hughes et al., 2004a; Rauch et al., 2006; Rodriguez-
Novoa et al., 2007; Waters et al., 2007; Zucman et al., 2007;
Mallal et al., 2008). The HLA-B∗57:01 allele has a high degree
of penetrance; the pooled odds ratio from three studies was
computed to be 29. Nevertheless, not all HLA-B∗57:01 carriers
would be hypersensitive toward abacavir; of every ten individuals
harboring the allele, only five would indeed develop a reaction
(Hetherington et al., 2002; Mallal et al., 2002; Hughes et al.,
2004a). It is likely that other gene loci or pathways, particularly
those implicated in the conversion of abacavir into allergenic
metabolites, have also contributed to the pathogenesis of abacavir
hypersensitivity (Martin et al., 2004, 2012).
Screening for HLA-B∗57:01 carriage, and using this
information to preclude susceptible individuals from receiving
abacavir, substantially reduced the incidence of abacavir
hypersensitivity, hence relieving the costs that would have
been incurred by the management of these reactions (Hughes
et al., 2004a; Schackman et al., 2008). The decrease in the
incidence of hypersensitivity reactions ranged from two-fold
(Waters et al., 2007; Mallal et al., 2008) or four-fold (Rauch
et al., 2006) to complete eradication (Zucman et al., 2007). The
cost-efficiency of HLA-B∗57:01 testing is ethnicity-dependent,
being largest in an all-Caucasian or a predominantly Caucasian
population. Individuals of other ethnic origins, such as Africans
(Hetherington et al., 2002; Hughes et al., 2004b) and Taiwanese
(Sun et al., 2007), derive little benefit from such a discriminative
strategy. The risk of developing abacavir hypersensitivity is
considerably lower in both populations (Symonds et al., 2002;
Sun et al., 2007). For instance, the incidence of abacavir-induced
hypersensitivity is only 0.9% among Taiwanese individuals,
coinciding with their equally rare carriage of the HLA-B∗57:01
allele (0.3% versus about 8% in Whites; Rauch et al., 2006; Sun
et al., 2007). Despite the obvious influence of individual ethnic
backgrounds, the Clinical Pharmacogenetics Implementation
Consortium has recommended HLA-B∗57:01 screening for all
patients before they are given abacavir (Martin et al., 2012, 2014).
Distinguishing HLA alleles could be challenging, as these alleles
may vary at only a few positions within their second and third
exons (Robinson et al., 2015).
Use of the MinION Device to Genotype
HLA Alleles
Several test options exist for HLA-B∗57:01 screening, with
sequence-based methods being most technically complex and
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deemed unsuited for routine use (Martin et al., 2012). These
methods often rely on PCRs to enrich the desired HLA regions
(Carapito et al., 2016). In a bespoke, PCR-based pipeline (Ammar
et al., 2015), the HLA-A and HLA-B regions were amplified in two
long-range PCRs and the resultant products (∼4 kb each) were
sequenced on MinION. The accuracy of the nanopore reads was
expectedly low, with the proportion of reference-discordant bases
nearing 30%. The authors surmised that this could have adversely
affected the genotyping results: the two samples trialed using this
method were both erroneously typed. The possibility of the HLA
haplotypes being obscured by PCR recombination or chimerism
was alluded to but not thoroughly discussed (Ammar et al., 2015;
Laver et al., 2016).
Cross-over extension or template switching is a well-known
PCR artifact whereby incompletely synthesized PCR products
(mega-primers) anneal to new templates giving rise to chimeric
alleles (Odelberg et al., 1995). Recombined alleles would
confound haplotype interpretation and it is noteworthy that
such errors are clinically significant and could diminish the
efficacy of MinION-centric approaches for HLA genotyping. For
instance, in the case of characterizing the BCR-ABL1 gene in
chronic myeloid leukemia, the occurrence of PCR recombination
was found to create artificial compound BCR-ABL1 mutations,
potentially misguiding anti-cancer therapy. After two rounds of
PCR, totalling 80 cycles, nearly 50% of the amplicons were noted
to be chimeric (Parker et al., 2014).
Several alterations could be made to the PCR protocol to
attenuate template switching. For instance, the extension time
could be prolonged to ensure complete synthesis of PCR products
in each cycle; or the number of PCR cycles curtailed to reduce
the probability of PCR recombination (McDonald et al., 2002;
Laver et al., 2016). Cross-over events are more likely to occur
near the end of PCR cycling or following numerous rounds
of extension, during which the synthesized products are most
concentrated. Alternatively, a different mechanism of enrichment
could be adopted to obviate the need for these changes. Short,
complementary oligonucleotides, acting as probes, can efficiently
capture target HLA regions from a pool of genomic DNAs that
have been trimmed to a pre-defined size range (Wittig et al.,
2015). For MinION, it may be necessary to opt for longer probes
(Karamitros and Magiorkinis, 2015) and a much less severe DNA
fragmentation protocol, in order to preserve the capacity of the
device to produce very long reads for the assembly of large-scale
haplotypes.
Presently, a more pressing concern over MinION is perhaps
its low base-calling accuracy; the error rate has frequently
been estimated to exceed 10% (Check Hayden, 2015). Previous
attempts at overcoming this problem have tackled chiefly two
aspects of the sequencing workflow: conversion of input DNAs
into sequenceable templates; and translation of ionic events
into DNA bases. The first tactic derives benefit from redundant
sequencing in that the input DNA is circularized and amplified
in a segmental manner (rolling circle amplification) to generate
tandem copies (≥6) of a segment for consensus sequence
determination (Li et al., 2016). This has resulted in greatly
increased read accuracy (>97%) that approach those attainable
by the second-generation platforms (Quail et al., 2012). However,
the cost of such improved accuracy is a reduced net output from
MinION; in other words, fewer bases are ultimately emitted per
run. The second tactic is based on statistical learning enhanced
by the rapidly expanding MinION datasets that are openly
accessible. This has enabled mature hidden Markov models to
be built for base-calling, establishing more precise event-to-
sequence patterns. The construction of a sophisticated artificial
neural network for DNA sequence deduction has also been
suggested as a solution to the conundrum (Jain et al., 2015; Boža
et al., 2016; David et al., 2016). Currently, it is uncertain which
of the two strategies is superior: modified template preparation
which adds some degree of complexity, or better trained in silico
algorithms?
The relatively time-consuming nature of sequence-based HLA
typing constitutes another limitation that must be overcome to
enable routine use of the technique. For instance, it may not
be uncommon for a MinION sequencing run to take one day,
though it is possible to analyze the data prior to conclusion
of the run. The requirement for long-range PCR amplification
to isolate HLA genes could easily lengthen the procedure to
span two days. For the synthesis of long amplicons, protracted
elongation time is an inevitable bottleneck; 30–60 s are typically
needed for the polymerization of ∼1000 nucleotides. A probe-
based protocol may entail an even longer time of 3–4 days;
but it offers the advantage of eradicating PCR chimerism by
needing only 18 cycles of amplification for the enrichment of
captured fragments (Karamitros and Magiorkinis, 2015; Laver
et al., 2016). On the other hand, an expedited long PCR protocol
may be formulated from the following ingredients: whole-blood
PCR which eliminates the need for DNA extraction (Mercier
et al., 1990), ultra-fast PCR empowered by prompt temperature
switches (Wheeler et al., 2011), and highly processive Taq
polymerases capable of incorporating nucleotides at a faster rate
(Böhlke et al., 2000).
CONCLUSION
As we have pointed out, several issues warrant deliberation before
MinION-based HLA typing could be considered for clinical
use. The unsatisfactory data accuracy is still an unresolved
issue. A modified preparatory protocol that unifies sequence
information from tandem copies of a DNA segment has been
shown to augment base-calling accuracy (Li et al., 2016). It may
be worthwhile to compare the performance of this technique with
other in silico approaches. The turnaround time for sequence-
based tests needs to be drastically shortened; also, the testing
process should be complemented by a streamlined mechanism
for data analysis, interpretation, and reporting. Spartan RX,
a panel indicated for the identification of CYP2C19 poor
metabolizers, can generate the required result within 1 h of
sample acquisition (Spartan Bioscience Inc., 2016). Above all,
the actual utility of sequence-based tests begs the question
as to whether the level of HLA genotype resolution achieved
by other quicker and less laborious methods, such as allele-
specific PCR, is already sufficient in the clinical setting (Martin
et al., 2012). Despite these uncertainties, the diverse utility of
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MinION is evident in the assortment of applications on which
it has been trialed. We are optimistic that MinION will be
eventually morphed into a potent tool for the diagnosis of drug
hypersensitivity.
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